Market Overview

Pain Therapeutics Gets a Complete Response Letter From the FDA Stating, 'The Data Submitted in [the] NDA Do Not Support the Conclusion That the Benefits of [REMOXY] Extended-Release Capsules Outweigh the Risks'

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Posted-In: News FDA

 

Related Articles (DRRX + PTIE)

Insider Buys Of The Week: Energen, Seagate, International Flavors And More

A Peek Into The Markets: US Stock Futures Up Ahead Of Earnings